SOURCE: PlasmaTech Biopharmaceuticals

PlasmaTech Biopharmaceuticals

May 26, 2015 13:15 ET

REMINDER: PlasmaTech Biopharmaceuticals First Quarter 2015 Conference Call Tomorrow

NEW YORK, NY--(Marketwired - May 26, 2015) - PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, will provide a business update for investors on a conference call tomorrow, Wednesday, May 27th, at 10:00 AM (EDT).

Steven H. Rouhandeh, Executive Chairman, and Tim Miller, Ph.D., President and CEO, together with other executives, will conduct the call. Interested parties are invited to participate in the call by dialing: Toll Free Number: 877-269-7756 or International Toll Number: 201-689-7817. The call will consist of an overview of the Company's first quarter Form 10-Q, and a discussion of business highlights and activities of the recently announced transactions. Immediately thereafter, there will be a question and answer period open to all registered analysts and investors. A recorded replay of the call will be available at the following toll free number: 877-660-6853 or international toll number 201-612-7415, and choose Conference ID 13610418.

About PlasmaTech Biopharmaceuticals: PlasmaTech Biopharmaceuticals is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. PlasmaTech's lead program is a gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015. In addition, the company is pursuing two additional proprietary platforms, Salt Diafiltration (SDF) Process and Polymer Hydrogel Technology (PHT), and is active in the development and commercialization of human plasma-derived therapeutics, including its proprietary alpha-1 protease inhibitor, SDF Alpha. The company has developed a robust product pipeline that includes two commercial stage products, MuGard® and ProctiGard, with additional follow-on products in development. For more information, visit www.plasmatechbio.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, those relating to: the Company's proposed acquisition of Abeona, anticipated acceleration in the development and internationalization of clinical programs, information regarding the future performance of the combined company, the outlook on medical needs, future pipeline expectations, management plans for the Company, the anticipated closing of the transaction, and general business outlook. These statements are subject to numerous risks and uncertainties, including but not limited the satisfaction of closing conditions for the transaction, the parties' ability to successfully integrate and operate the new company, and achieve expected synergies and other benefits; the impact of competition; the ability to develop products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Contact Information

  • Company and Media Contact:

    Andre'a Lucca
    Director of Communications
    PlasmaTech Biopharmaceuticals, Inc.
    212-786-6208
    alucca@plasmatechbio.com